Decitabine (Dacogen; MGI Pharma), a nucleoside analogue that inhibits DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2006.
|Original language||English (US)|
|Number of pages||2|
|Journal||Nature Reviews Drug Discovery|
|State||Published - Nov 2006|
ASJC Scopus subject areas
- Drug Discovery